Last reviewed · How we verify
anti-CD7 CAR-pNK cells — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
anti-CD7 CAR-pNK cells (anti-CD7 CAR-pNK cells) — PersonGen BioTherapeutics (Suzhou) Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| anti-CD7 CAR-pNK cells TARGET | anti-CD7 CAR-pNK cells | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- anti-CD7 CAR-pNK cells CI watch — RSS
- anti-CD7 CAR-pNK cells CI watch — Atom
- anti-CD7 CAR-pNK cells CI watch — JSON
- anti-CD7 CAR-pNK cells alone — RSS
Cite this brief
Drug Landscape (2026). anti-CD7 CAR-pNK cells — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-cd7-car-pnk-cells. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab